Eli Lilly and Company (LLY)

US — Healthcare Sector
Peers: JNJ  BMY  ABBV  PFE  MRK  AMGN  GILD 

Automate Your Wheel Strategy on LLY

With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LLY
  • Rev/Share 54.5268
  • Book/Share 17.633
  • PB 41.1914
  • Debt/Equity 2.4432
  • CurrentRatio 1.3723
  • ROIC 0.2572

 

  • MktCap 684805601520.0
  • FreeCF/Share 0.5421
  • PFCF 1405.5944
  • PE 58.4684
  • Debt/Assets 0.4309
  • DivYield 0.0078
  • ROE 0.7692

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LLY HSBC Securities Buy Reduce $1150 $700 April 28, 2025
Initiation LLY Cantor Fitzgerald -- Overweight -- $975 April 22, 2025
Resumed LLY BofA Securities -- Buy -- $997 Dec. 10, 2024
Initiation LLY Bernstein -- Outperform -- $1100 Oct. 17, 2024
Resumed LLY Citigroup -- Buy -- $1060 Sept. 13, 2024

News

LLY Rises More Than 4% in a Week: How to Play the Stock
LLY
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Read More
image for news LLY Rises More Than 4% in a Week: How to Play the Stock
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
LLY
Published: February 13, 2025 by: MarketBeat
Sentiment: Positive

Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.

Read More
image for news Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
LLY
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.

Read More
image for news GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?

About Eli Lilly and Company (LLY)

  • IPO Date 1972-06-01
  • Website https://www.lilly.com
  • Industry Drug Manufacturers - General
  • CEO Mr. David A. Ricks
  • Employees 47000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.